Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.

Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, Settas L, Zisopoulos D, Iliopoulos A, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P.

J Rheumatol. 2018 Jun;45(6):785-794. doi: 10.3899/jrheum.170477. Epub 2018 Apr 1.

2.

Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden.

Einarsson JT, Willim M, Ernestam S, Saxne T, Geborek P, Kapetanovic MC.

Rheumatology (Oxford). 2018 Mar 12. doi: 10.1093/rheumatology/key054. [Epub ahead of print]

PMID:
29538755
3.

Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis.

Hesselstrand R, Nagel J, Saxne T, Geborek P, Skattum L, Kapetanovic MC.

Rheumatology (Oxford). 2018 Apr 1;57(4):769. doi: 10.1093/rheumatology/key007. No abstract available.

PMID:
29373696
4.

Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis.

Hesselstrand R, Nagel J, Saxne T, Geborek P, Skattum L, Kapetanovic MC.

Rheumatology (Oxford). 2018 Apr 1;57(4):625-630. doi: 10.1093/rheumatology/kex471. Erratum in: Rheumatology (Oxford). 2018 Apr 1;57(4):769.

PMID:
29325173
5.

Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.

Einarsson JT, Evert M, Geborek P, Saxne T, Lundgren M, Kapetanovic MC.

Clin Rheumatol. 2017 Dec;36(12):2743-2750. doi: 10.1007/s10067-017-3848-6. Epub 2017 Oct 4.

6.

Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy.

Nived P, Nagel J, Saxne T, Geborek P, Jönsson G, Skattum L, Kapetanovic MC.

Vaccine. 2017 Jun 22;35(29):3639-3646. doi: 10.1016/j.vaccine.2017.05.044. Epub 2017 May 25.

PMID:
28552512
7.

Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis.

Berthold E, Månsson B, Gullstrand B, Geborek P, Saxne T, Bengtsson AA, Kahn R.

Scand J Rheumatol. 2018 Jan;47(1):22-26. doi: 10.1080/03009742.2017.1290822. Epub 2017 May 9.

PMID:
28485187
8.

Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.

Nagel J, Saxne T, Geborek P, Bengtsson AA, Jacobsen S, Svaerke Joergensen C, Nilsson JÅ, Skattum L, Jönsen A, Kapetanovic MC.

Lupus. 2017 Sep;26(10):1072-1081. doi: 10.1177/0961203317695465. Epub 2017 Feb 26.

PMID:
28420056
9.

EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.

Jørgensen TS, Turesson C, Kapetanovic M, Englund M, Turkiewicz A, Christensen R, Bliddal H, Geborek P, Kristensen LE.

PLoS One. 2017 Feb 2;12(2):e0169946. doi: 10.1371/journal.pone.0169946. eCollection 2017.

10.

Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.

Kapetanovic MC, Nagel J, Nordström I, Saxne T, Geborek P, Rudin A.

Vaccine. 2017 Feb 7;35(6):903-908. doi: 10.1016/j.vaccine.2016.12.068. Epub 2017 Jan 9.

PMID:
28081972
11.

Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?

Olofsson T, Petersson IF, Eriksson JK, Englund M, Nilsson JA, Geborek P, Jacobsson LTH, Askling J, Neovius M; ARTIS Study Group.

Ann Rheum Dis. 2017 Jul;76(7):1245-1252. doi: 10.1136/annrheumdis-2016-210239. Epub 2017 Jan 10.

PMID:
28073801
12.

Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden.

Wallman JK, Eriksson JK, Nilsson JÅ, Olofsson T, Kristensen LE, Neovius M, Geborek P.

J Rheumatol. 2016 Jul;43(7):1292-9. doi: 10.3899/jrheum.150617. Epub 2016 Jun 1.

PMID:
27252420
13.

Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.

Einarsson JT, Geborek P, Saxne T, Kristensen LE, Kapetanovic MC.

J Rheumatol. 2016 Jun;43(6):1017-23. doi: 10.3899/jrheum.150995. Epub 2016 Apr 1.

PMID:
27036384
14.

Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.

Kahn R, Berthold E, Gullstrand B, Schmidt T, Kahn F, Geborek P, Saxne T, Bengtsson AA, Månsson B.

Acta Paediatr. 2016 Apr;105(4):427-32. doi: 10.1111/apa.13319. Epub 2016 Feb 1.

16.

Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.

Kristensen LE, Lie E, Jacobsson LT, Christensen R, Mease PJ, Bliddal H, Geborek P.

J Rheumatol. 2016 Jan;43(1):81-7. doi: 10.3899/jrheum.150744. Epub 2015 Dec 1.

PMID:
26628604
17.

Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion.

van Vollenhoven RF, Bolce R, Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Sasso EH, Hwang CC, Segurado OG, Geborek P.

Arthritis Rheumatol. 2015 Nov;67(11):2855-60. doi: 10.1002/art.39274.

18.

The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients.

Nagel J, Geborek P, Saxne T, Jönsson G, Englund M, Petersson IF, Nilsson JÅ, Truedsson L, Kapetanovic MC.

Arthritis Res Ther. 2015 May 19;17:124. doi: 10.1186/s13075-015-0636-z.

19.

Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.

Einarsson JT, Geborek P, Saxne T, Kapetanovic MC.

J Rheumatol. 2015 May;42(5):741-8. doi: 10.3899/jrheum.131502. Epub 2015 Feb 15.

PMID:
25684762
20.

The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients.

Nagel J, Geborek P, Saxne T, Jönsson G, Englund M, Petersson IF, Nilsson JÅ, Kapetanovic MC.

Scand J Rheumatol. 2015;44(4):271-9. doi: 10.3109/03009742.2014.984754. Epub 2015 Feb 6.

PMID:
25656734
21.

Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.

Kastbom A, Forslind K, Ernestam S, Geborek P, Karlsson JA, Petersson IF, Saevarsdottir S, Klareskog L, van Vollenhoven RF, Lundberg K.

Ann Rheum Dis. 2016 Feb;75(2):356-61. doi: 10.1136/annrheumdis-2014-205698. Epub 2014 Dec 30.

22.

Properties of bilateral spinocerebellar activation of cerebellar cortical neurons.

Geborek P, Bengtsson F, Jörntell H.

Front Neural Circuits. 2014 Oct 27;8:128. doi: 10.3389/fncir.2014.00128. eCollection 2014.

23.

Simulating spinal border cells and cerebellar granule cells under locomotion--a case study of spinocerebellar information processing.

Spanne A, Geborek P, Bengtsson F, Jörntell H.

PLoS One. 2014 Sep 16;9(9):e107793. doi: 10.1371/journal.pone.0107793. eCollection 2014.

24.

Development of functional impairment and disability in rheumatoid arthritis patients followed for 20 years: relation to disease activity, joint damage, and comorbidity.

Kapetanovic MC, Lindqvist E, Nilsson JÅ, Geborek P, Saxne T, Eberhardt K.

Arthritis Care Res (Hoboken). 2015 Mar;67(3):340-8. doi: 10.1002/acr.22458.

25.

Segregation of tactile input features in neurons of the cuneate nucleus.

Jörntell H, Bengtsson F, Geborek P, Spanne A, Terekhov AV, Hayward V.

Neuron. 2014 Sep 17;83(6):1444-52. doi: 10.1016/j.neuron.2014.07.038. Epub 2014 Aug 28.

26.

Spike generation estimated from stationary spike trains in a variety of neurons in vivo.

Spanne A, Geborek P, Bengtsson F, Jörntell H.

Front Cell Neurosci. 2014 Jul 25;8:199. doi: 10.3389/fncel.2014.00199. eCollection 2014.

27.

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, Forslind K, Petersson IF, Geborek P, van Vollenhoven RF.

Ann Rheum Dis. 2015 Jun;74(6):1102-9. doi: 10.1136/annrheumdis-2013-204986. Epub 2014 May 8.

28.

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.

Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, Geborek P, Neovius M.

Ann Rheum Dis. 2015 Jun;74(6):1094-101. doi: 10.1136/annrheumdis-2013-205060. Epub 2014 Apr 15.

29.

Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.

Saevarsdottir S, Rezaei H, Geborek P, Petersson I, Ernestam S, Albertsson K, Forslind K, van Vollenhoven RF; SWEFOT study group.

Ann Rheum Dis. 2015 Aug;74(8):1509-14. doi: 10.1136/annrheumdis-2013-204601. Epub 2014 Apr 4.

30.

Spatio-temporal skin strain distributions evoke low variability spike responses in cuneate neurons.

Hayward V, Terekhov AV, Wong SC, Geborek P, Bengtsson F, Jörntell H.

J R Soc Interface. 2014 Jan 22;11(93):20131015. doi: 10.1098/rsif.2013.1015. Print 2014 Apr 6.

31.

Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.

Kapetanovic MC, Kristensen LE, Saxne T, Aktas T, Mörner A, Geborek P.

Arthritis Res Ther. 2014 Jan 2;16(1):R2. doi: 10.1186/ar4427.

32.

Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.

Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P.

Arthritis Res Ther. 2013 Oct 30;15(5):R171. doi: 10.1186/ar4358.

33.

Cerebellar cortical neuron responses evoked from the spinal border cell tract.

Geborek P, Spanne A, Bengtsson F, Jörntell H.

Front Neural Circuits. 2013 Oct 8;7:157. doi: 10.3389/fncir.2013.00157. eCollection 2013.

34.
35.

Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.

Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P.

Semin Arthritis Rheum. 2014 Feb;43(4):447-57. doi: 10.1016/j.semarthrit.2013.07.011. Epub 2013 Sep 6.

PMID:
24012040
36.

Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.

Kristensen LE, Bliddal H, Christensen R, Karlsson JA, Gülfe A, Saxne T, Geborek P.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):173-9. doi: 10.1002/acr.22107.

37.

Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.

Eriksson JK, Neovius M, Bratt J, Petersson IF, van Vollenhoven RF, Geborek P, Ernestam S.

JAMA Intern Med. 2013 Aug 12;173(15):1407-14. doi: 10.1001/jamainternmed.2013.7801.

PMID:
23817631
38.

Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort.

Olofsson T, Petersson IF, Eriksson JK, Englund M, Simard JF, Nilsson JÅ, Geborek P, Jacobsson LT, Askling J, Neovius M.

Ann Rheum Dis. 2014 May;73(5):845-53. doi: 10.1136/annrheumdis-2012-202911. Epub 2013 Mar 21.

PMID:
23520035
39.

Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.

Rezaei H, Saevarsdottir S, Geborek P, Petersson IF, van Vollenhoven RF, Forslind K.

BMC Musculoskelet Disord. 2013 Mar 5;14:79. doi: 10.1186/1471-2474-14-79.

40.

Stimulation within the cuneate nucleus suppresses synaptic activation of climbing fibers.

Geborek P, Jörntell H, Bengtsson F.

Front Neural Circuits. 2013 Jan 17;6:120. doi: 10.3389/fncir.2012.00120. eCollection 2012.

41.
42.

Cross-correlations between pairs of neurons in cerebellar cortex in vivo.

Bengtsson F, Geborek P, Jörntell H.

Neural Netw. 2013 Nov;47:88-94. doi: 10.1016/j.neunet.2012.11.016. Epub 2012 Dec 6.

43.

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.

Karlsson JA, Neovius M, Nilsson JÅ, Petersson IF, Bratt J, van Vollenhoven RF, Ernestam S, Geborek P.

Ann Rheum Dis. 2013 Dec;72(12):1927-33. doi: 10.1136/annrheumdis-2012-202062. Epub 2012 Nov 29.

PMID:
23196701
44.

A survey of spinal collateral actions of feline ventral spinocerebellar tract neurons.

Geborek P, Nilsson E, Bolzoni F, Jankowska E.

Eur J Neurosci. 2013 Feb;37(3):380-92. doi: 10.1111/ejn.12060. Epub 2012 Nov 21.

PMID:
23167927
45.

The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice.

Lekander I, Borgström F, Lysholm J, van Vollenhoven RF, Lindblad S, Geborek P, Kobelt G.

Eur J Health Econ. 2013 Dec;14(6):863-73. doi: 10.1007/s10198-012-0431-6. Epub 2012 Sep 19.

PMID:
22990378
46.

Individualized outcome measures of daily activities are sensitive tools for evaluating hand surgery in rheumatic diseases.

Malcus Johnsson P, Sandqvist G, Sturesson AL, Gulfe A, Kopylov P, Tägil M, Geborek P.

Rheumatology (Oxford). 2012 Dec;51(12):2246-51. doi: 10.1093/rheumatology/kes224. Epub 2012 Sep 1.

PMID:
22942405
47.

Extra-articular manifestations in a community-based sample of patients with rheumatoid arthritis: incidence and relationship to treatment with TNF inhibitors.

Nyhäll-Wåhlin BM, Petersson IF, Jacobsson C, Geborek P, Nilsson JÅ, Nilsson K, Jacobsson LT, Turesson C.

Scand J Rheumatol. 2012;41(6):434-7. doi: 10.3109/03009742.2012.695803. Epub 2012 Jul 20.

PMID:
22813208
48.

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, Chatzidionysiou K, Bratt J; Swefot study group.

Lancet. 2012 May 5;379(9827):1712-20. doi: 10.1016/S0140-6736(12)60027-0. Epub 2012 Mar 29.

PMID:
22464340
49.

Decreased neutrophil apoptosis in quiescent ANCA-associated systemic vasculitis.

Abdgawad M, Pettersson Å, Gunnarsson L, Bengtsson AA, Geborek P, Nilsson L, Segelmark M, Hellmark T.

PLoS One. 2012;7(3):e32439. doi: 10.1371/journal.pone.0032439. Epub 2012 Mar 5.

50.

Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment.

Happonen KE, Saxne T, Geborek P, Andersson M, Bengtsson AA, Hesselstrand R, Heinegård D, Blom AM.

Arthritis Res Ther. 2012 Jan 20;14(1):R15. doi: 10.1186/ar3694.

Supplemental Content

Loading ...
Support Center